The R1623Q mutation causes a severe long-QT phenotype through unique inactivation gating defects that prolong sodium current decay, which can be reversed by lidocaine.
Answers are grounded in this paper and cite their sources.
Lidocaine may correct R1623Q sodium defects in models; leaves open clinical translation and patient benefit.
BACKGROUND: A heritable form of the long-QT syndrome (LQT3) has been linked to mutations in the cardiac sodium channel gene (SCN5A). Recently, a sporadic SCN5A mutation was identified in a Japanese girl afflicted with the long-QT syndrome. In contrast to the heritable mutations, this externally positioned domain IV, S4 mutation (R1623Q) neutralized a charged residue that is critically involved in activation-inactivation coupling. METHODS AND RESULTS: We have characterized the R1623Q mutation in the human cardiac sodium channel (hH1) using both whole-cell and single-channel recordings. In contrast to the autosomal dominant LQT3 mutations, R1623Q increased the probability of long openings and caused early reopenings, producing a threefold prolongation of sodium current decay. Lidocaine restored rapid decay of the R1623Q macroscopic current. CONCLUSIONS: The R1623Q mutation produces inactivation gating defects that differ mechanistically from those caused by LQT3 mutations. These findings provide a biophysical explanation for this severe long-QT phenotype and extend our understanding of the mechanistic role of the S4 segment in cardiac sodium channel inactivation gating and class I antiarrhythmic drug action.
No takes yet. Share an insight, caveat, or question.
Kambouris et al. (1998) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: